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Cytoplasmic glycoengineering enables biosynthesis
of nanoscale glycoprotein assemblies
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Glycosylation of proteins profoundly impacts their physical and biological properties. Yet our
ability to engineer novel glycoprotein structures remains limited. Established bacterial gly-
coengineering platforms require secretion of the acceptor protein to the periplasmic space
and preassembly of the oligosaccharide substrate as a lipid-linked precursor, limiting access
to protein and glycan substrates respectively. Here, we circumvent these bottlenecks by
developing a facile glycoengineering platform that operates in the bacterial cytoplasm. The
Glycoli platform leverages a recently discovered site-speciﬁc polypeptide glycosyltransferase
together with variable glycosyltransferase modules to synthesize deﬁned glycans, of bacterial
or mammalian origin, directly onto recombinant proteins in the E. coli cytoplasm. We exploit
the cytoplasmic localization of this glycoengineering platform to generate a variety of mul-
tivalent glycostructures, including self-assembling nanomaterials bearing hundreds of copies
of the glycan epitope. This work establishes cytoplasmic glycoengineering as a powerful
platform for producing glycoprotein structures with diverse future biomedical applications.
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Across the domains of life, the cell’s outermost surface isdecorated with a dense array of complex carbohydrates1.These sugars are conduits for cell adhesion and commu-
nication, and mediators of host–microbe interactions2, making
them attractive targets for therapeutic intervention. Yet our
ability to produce and engineer complex carbohydrates lags far
behind the other major classes of biological macromolecules.
Glycoproteins are among the most structurally diverse class of
glycoconjugates. The functional repertoire and versatility of the
proteome is massively expanded by the posttranslational attach-
ment of monosaccharides, oligosaccharides, or polysaccharides to
proteins3. In the case of therapeutic proteins, more than 70% are
glycosylated, and optimizing glycosylation can considerably
beneﬁt therapeutic efﬁcacy4. To facilitate glycoengineering of the
current generation of therapeutic proteins—including mAbs,
hormones, and blood factors—the community has made impor-
tant progress in engineering the glycosylation pathways of
mammalian5, plant6, yeast7, and insect cells8 towards homo-
genous and humanized glycosylation proﬁles. On the other hand,
glycoprotein engineering in bacterial cells has provided access to
unprecedented structures with applications as next-generation
glycoconjugate vaccines and diagnostic reagents9.
The most advanced strategies for recombinant glycoprotein
synthesis in Escherichia coli exploit periplasmic oligosaccharyl-
transferase (OST)-based pathways. OSTs are integral membrane
proteins with a catalytic domain facing the lumen of the peri-
plasm, where they catalyze glycosylation of proteins using lipid-
linked oligosaccharides (LLO) as donor substrates. Three factors
enable periplasmic glycoengineering: (i) the promiscuity of some
OSTs towards different glycans presented on the appropriate
lipid10,11, (ii) the ability to target heterologous proteins for gly-
cosylation by introducing an appropriate sequence motif12,13, and
(iii) a functional biosynthetic pathway (native or engineered) for
producing the desired LLO. Limitations of periplasmic gly-
coengineering include the difﬁculty of engineering novel LLO
biosynthesis pathways14,15, the limited substrate promiscuity of
OSTs11,16, and the requirement to secrete acceptor proteins into
the periplasm for glycosylation to occur. To provide access to new
areas of glycoprotein structural space, it is essential that we
develop alternative routes for bacterial glycoengineering that are
not dependent on LLO intermediates, and that do not operate in
the periplasm.
The cytoplasm of E. coli is a robust and versatile compartment
for recombinant protein expression. Recent studies have shown
that proteins that form functional nanoscale, megadalton
assemblies can be produced in the bacterial cytoplasm17–19. For
example, the natural cage-forming protein, lumazine synthase
from Aquifex aeolicus (AaLS) was engineered and evolved to
encapsulate various guest molecules including enzymes20,21,
ﬂuorescent proteins22, and most recently its own RNA
genome23,24. Such nucleocapsids are evolvable nanostructures
that can be quickly adapted to acquire important properties, such
as the ability to protect cargo against nucleases24 or increased
circulatory half-life in bodily ﬂuids25. These self-assembling
proteins have recently attracted attention as tailored vehicles for
drug delivery and vaccination. Glycosylation of the nanoparticle
surface holds the potential to expand their utility in these appli-
cations, giving strong impetus to the development of cytoplasmic
glycoengineering pathways.
The identiﬁcation of cytoplasmic protein glycosylation systems
in various bacterial species, presents exciting opportunities for
cytoplasmic glycoengineering9,26. We have chosen the asparagine
(N)-glucosyltransferase of Actinobacillus pleuropneumoniae
(ApNGT) as the basis for a cytoplasmic glycoengineering plat-
form. The ApNGT can be actively expressed in the E. coli cyto-
plasm and catalyzes the transfer of a single β-linked glucose onto
recombinant proteins at the N-x-S/T consensus sequon27–29.
We have shown that this short sequon can be exploited to
target glycosylation of heterologous proteins, such as the super-
folder green ﬂuorescent protein (sfGFP)30 and next-generation
antibody mimetics, such as designed ankyrin-repeat proteins
(DARPin)31,32. In this study, we demonstrate that N-linked
glucose (N-Glc) can be used as a site-speciﬁc primer for the
biosynthesis of diverse oligosaccharides and polysaccharides
directly onto recombinant proteins in the cytoplasm. We exploit
the cytoplasmic localization of these artiﬁcial glycosylation
pathways to generate a variety of self-assembling glycoproteins
that form icosahedral nanostructures with future applications as
vaccines and drug-delivery vehicles.
Results
A modular protein glycoengineering toolbox. We have pre-
viously demonstrated the site-speciﬁc synthesis of N-linked lac-
tose onto a protein target in E. coli32. The lactose disaccharide is
present at the reducing end of a variety of common mammalian
glycans, including human milk oligosaccharides (HMOs) and
glycosphingolipids, making it an attractive primer for glycan
biosynthesis. Furthermore, numerous biosynthetic pathways have
been developed for the production of free oligosaccharides in E.
coli using a lactose primer33–36. Drawing on this work, we
designed protein glycosylation pathways for a range of biome-
dically relevant glycan epitopes (Fig. 1a).
The proposed biosynthetic pathways require co-expression of
up to six enzymes from different bacterial species. To efﬁciently
generate pathway constructs in a modular and tunable manner,
we chose to combine BioBricked pathway elements (e.g. one
glycosyltransferase or one nucleotide–sugar biosynthesis path-
way) on plasmid backbones conforming to the standard
European vector architecture (SEVA)37. Each glycosyltransferase
brick comprised a single expression cassette including a variable
promoter (lacUV5, or T5), a ribosome-binding site, the relevant
open-reading frame, and a T7 terminator, ﬂanked by the BioBrick
preﬁx and sufﬁx (Supplementary Fig. 1)38. We assembled
pathway constructs (up to 13.6 kb in size) for a total of nine
glycan structures, none of which, to the best of our knowledge,
are accessible to existing protein glycoengineering platforms.
Cytoplasmic glycosylation of proteins. To screen prototype
pathways for glycan assembly, they were co-expressed with a
model target protein, sfGFP carrying a C-terminal extension
possessing a single glycosylation site (Asn-Ala-Thr; Supplemen-
tary Fig. 2)32. The target protein was afﬁnity puriﬁed and ana-
lyzed by mass spectrometry (MS). Throughout the study, we
observed glycosylation exclusively at the target site, Asn263, of
the sfGFP construct. The yield of sfGFP also remained constant at
~30 mg L−1 from shaker ﬂask culture irrespective of the glyco-
sylation pathway.
We ﬁrst established the capacity to modify proteins with
common mammalian oligosaccharide epitopes, including: 2′-
fucosyllactose, 3′-sialyllactose, oligosialyllactose, N-acetyllactosa-
mine (LacNAc) repeats, and the LewisX blood group antigen.
These pathways combine glycosyltransferases from lipooligosac-
charide or lipopolysaccharide biosynthesis from different bacter-
ial species (Supplementary Table 1). Our LC–MS/MS analysis of
tryptic peptides from the puriﬁed pathway products conﬁrmed
site-speciﬁc synthesis of all target glycan structures onto the
protein substrate (Supplementary Figs. 3 and 4). To analyze site-
occupancy and glycoform distribution we performed intact
protein MS of proteins modiﬁed with glucose, lactose, 2′-
fucosyllactose and 3′-sialyllactose. This semi-quantitative analysis
indicated that the average (mean ± s.d., n= 3) occupancy of the
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Fig. 1 Cytoplasmic protein glycosylation. a Overview of protein glycosylation pathways. The protein–glycan linkage is established by transfer of a single
glucose onto an asparagine residue, in the N-x-S/T sequon (where, x≠ P), by the N-glucosyltransferase (NGT). The N-linked glucose (N-Glc) serves as a
primer for combinations of glycosyltransferases from different bacterial species to synthesize a variety of oligosaccharide or polysaccharide structures on
the target protein. Following co-expression with the respective glycosylation pathway, the (glyco)protein products were puriﬁed and analyzed by MS, SDS-
PAGE, or analytical anion exchange chromatography. Mass spectra of intact proteins modiﬁed with b glucose, c lactose, d 3′-sialyllactose (3′SL), and e 2′-
fucosyllactose. f Coomassie-stained SDS–PAGE of fractions from preparative anion exchange chromatography of GFP modiﬁed with CPSNmB. g Puriﬁed,
polysialylated GFP fractions modiﬁed with CPSNmB and CPSNmC were analyzed by anion exchange chromatography. The number of sialic acids in the
polysaccharide are indicted as degree of polymerization (DP). Sugar symbols are drawn according to the guidelines of the Consortium for Functional
Glycomics. Blue and yellow circles represent glucose and galactose, respectively. Red triangles and purple diamonds indicate fucose and sialic acid,
respectively. Source data are provided as a Source Data ﬁle.
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target sugars were 100%, 93 ± 1%, 79 ± 10%, and 62 ± 16%,
respectively, with minor portions remaining unmodiﬁed or
carrying a lactose intermediate (Fig. 1b–e and Supplementary
Fig. 5). We used anion exchange chromatography to indepen-
dently quantify the occupancy of the 3′-sialyllactose modiﬁcation.
We observed an average (mean ± s.d., n= 3) of 60 ± 8%
occupancy (Supplementary Fig. 6), in excellent agreement with
the MS-based analysis.
Varying pathway promoters can inﬂuence glycosylation
products. The ﬁrst version of each glycosylation pathway was
constructed with a lacUV5 promoter driving expression of each
glycosyltransferase. These constructs were effective for glucose,
lactose, 2′-fucosyllactose, and 3′-sialyllactose (described above).
In the case of two structures, LewisX and LacNAc repeats, we only
observed synthesis of the target glycan when the GlcNAc
transferase, LgtA, was expressed from the strong T5 promoter.
In this case, LC–MS/MS analysis indicated that the occupancy of
these glycans was low (<5%). We expect that more subtle tuning
of enzyme expression levels will be necessary to maximize ﬂux
through these artiﬁcial glycosylation pathways.
We next aimed to modify proteins with the capsular
polysaccharides of Gram-negative bacterial pathogens, which
are important targets for vaccination. Glycoconjugate vaccines—
consisting of the pathogen-speciﬁc capsular polysaccharide
chemically cross-linked to an antigenic carrier protein—currently
confer protection against, e.g. Haemophilus inﬂuenzae group B
and Neisseria meningitidis serogroups A, C, W-135, and Y39. To
facilitate complete biosynthesis of glycoconjugate vaccines in the
cytoplasm, we aimed to develop glycoengineering pathways that
synthesize capsular polysaccharides directly onto protein targets.
We previously demonstrated protein-coupled biosynthesis of
the nonimmunogenic polysaccharide of N. meningitidis ser-
ogroup B32. The immunogenic polysaccharide of N. meningitidis
serogroup C is a related homopolymer of sialic acids in α2,9-
linkage, and the respective capsule polymerase can be primed
with a trisaccharide of sialic acid40. We generated pathways for
both the NmB and NmC polysaccharide by combining the
respective capsule polymerase with the oligosialyllactose pathway
and the sfGFP acceptor. In both cases, MS analysis indicated
modiﬁcation of the protein with a homopolymer of sialic acid
(Supplementary Fig. 7), linkage of the NmB and NmC
polysaccharides was conﬁrmed using capsule-speciﬁc antibodies
(Supplementary Fig. 7). Although only a minor fraction (~15%)
of total protein was modiﬁed with polysaccharide, we used
preparative anion exchange chromatography to fractionate
the glycoprotein products according to the size of attached
polysaccharide (Fig. 1f). In this way, NmB-polysialylated
and NmC-polysialylated proteins were puriﬁed with yields
of 2150 and 750 μg L−1, respectively, from shaker ﬂask
culture. The products had distinct chain-length distributions
(Fig. 1g). Consistent with observations in vitro40, the NmC-
polysialyltransferase exhibited a bi-modal product distribution
including a population carrying very long chains.
These results highlight the versatility of cytoplasmic glycoen-
gineering to provide access to both small mammalian carbohy-
drate epitopes, as well as large polysaccharides associated with the
surface of bacterial pathogens.
Multivalent glycopolymers. Multivalency is a common theme in
glycobiology. Due to the generally low afﬁnities of glycan–protein
interactions, biological systems typically exploit multiple simul-
taneous interactions to achieve functionally relevant avidities41.
In our ﬁrst approach to multivalent glycan display, we introduced
multiple glycosylation sites along a single polypeptide chain.
Based on a consensus sequence [GANATA] for the ApNGT27, we
designed three repeat motifs with different spacing between the
glycosites: [GNAT]5, [GANATA]5, and [TAGANATA]5. These
sequences were genetically fused to the C-terminus of sfGFP and
co-expressed with the ApNGT. Denaturing PAGE revealed a
considerable increase in the apparent molecular weight of these
constructs upon co-expression with the ApNGT (Fig. 2a). The
modiﬁed species reacted strongly with an N-Glc-speciﬁc anti-
serum, MS1428,42. MS analysis conﬁrmed glycosylation of the
target asparagine residues and demonstrated that for all three
repeat sequences, the predominant species (>80% of total) was
completely glycosylated, carrying a glucose at all ﬁve sites (Sup-
plementary Fig. 8).
To test if we could generate a uniform, multivalent
glycoprotein, we increased the amount of NGT activity in the
cytoplasm using an alternative ApNGT expression plasmid.
Both plasmids express the ApNGT behind a lacUV5 promoter
and encode chloramphenicol resistance, but differ in the
presence of a pBBR1 replicon (~5 copies per chromosome) or
a p15A replicon (~8.6 copies per chromosome)43. Each plasmid
was co-expressed with the [GANATA]5-tagged construct. Intact
protein MS of the puriﬁed products revealed 93 ± 6% (mean ± s.d.,
n= 3) of the protein was modiﬁed with ﬁve glucose residues
when co-expressed with the lower copy pBBR1 plasmid. In our
analysis of products from the higher copy p15A plasmid, we
were unable to detect species with <100% occupancy (n= 3),
suggesting quantitative modiﬁcation of the protein (Fig. 2b).
These results demonstrate that improved glycosylation efﬁciency
may be achieved with minor adjustments to enzyme expression
levels.
Finally, we tested whether the closely located glucose
modiﬁcations could be extended by further glycosyltransferases.
The [GANATA]5-tagged construct was co-expressed with the
established pathways for lactose, 2′-fucosyllactose and 3′-
sialyllactose. The LC–MS/MS data conﬁrmed the presence of
heavily glycosylated proteins carrying up to ﬁve copies of the
target oligosaccharide (Fig. 2c–e and Supplementary Fig. 8).
Lactose was assembled with good efﬁciency on all ﬁve sites, with
69 ± 18% (mean ± s.d., n= 2) of the protein fully modiﬁed. A
much smaller portion of the protein (<5%) was completely
modiﬁed with the 2′-fucosyllactose or 3′-sialyllactose at all ﬁve
sites. These results indicate that a considerable increase in
pathway efﬁciency will be necessary to achieve full occupancy of
multivalent glycopolymers44. The ability to increase the valency
of glycan display—producing structures reminiscent of mucins
and lectin-blocking glycopolymers—will be critical for exploiting
the biological interactions of these common oligosaccharide
epitopes44,45.
Glycosylation of megadalton protein assemblies. With the
Glycoli platform established, we exploited its cytoplasmic locali-
zation to modify proteins that have remained inaccessible to
existing periplasmic glycoengineering systems. A class of proteins
that have been the center of much recent innovation are
self-assembling polypeptides that form protein cages17–19,
nucleocapsids24,25, and virus-like particles (VLPs)46,47. We chose
to target three megadalton-scale protein assemblies for glycosy-
lation: (i) the AP205 VLP is composed of 180 copies of the coat
protein of Acinetobacter phage 20548, and is a potently immu-
nogenic scaffold for presentation of vaccine antigens49; (ii) AaLS-
13, an engineered lumazine synthase that assembles into a six
megadalton porous cage composed of 360 identical monomers
and efﬁciently loads cargo molecules via electrostatic interac-
tions19–21,50; (iii) I53-50-v4 is composed of two polypeptide
sequences, which form trimeric and pentameric subunits that co-
assemble into 120-mer protein assemblies17, which have been
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adapted by directed evolution to package and protect their own
RNA genome25.
To decorate these structures with glycans, we introduced
glycosylation sites at surface exposed regions of the protein
subunits and co-expressed them with ApNGT. We observed an
increase in the mass of each of the targeted polypeptides
corresponding to the addition of a single hexose (Fig. 3a–c). In
the case of the AP205 VLP and AaLS-13, unmodiﬁed protein is
not detected in the mass spectra, indicating quantitative
modiﬁcation of the proteins. Upon addition of a trivalent tag to
AaLS-13, we observed the addition of up to three glucose residues
per monomer (average of two hexoses), generating structures that
present an average of 720 sugars across the surface (Supplemen-
tary Fig. 9). Transmission electron microscopy conﬁrmed that
these particle assemblies retain the original morphology upon
introduction of glycosylation sites and glycans (Fig. 3).
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Fig. 2 Multivalent glycopolymers. a Substrate proteins bearing a variety of pentavalent glycotags were co-expressed with and without the NGT, afﬁnity
puriﬁed, and analyzed by denaturing PAGE followed by Coomassie staining or immunoblot using an N-Glc-reactive serum. b Intact protein mass spectra of
GFP-[GANATA]5 expressed alone (upper panel) or with ApNGT from a p15A replicon plasmid (lower panel), showing uniform modiﬁcation with ﬁve
N-linked glucose residues. c–e Peptide LC–MS spectra show the glycosylation proﬁle of the GFP-[GANATA]5 substrate protein following co-expression
with the established pathways for c lactose, d 2′-fucosyllactose, and e 3′-sialyllactose. The assigned structures are supported by HCD–MS/MS spectra
(Supplementary Fig. 8). Blue, yellow, and white circles represent glucose, galactose, and hexose, respectively. Red triangles and purple diamonds indicate
fucose and sialic acid, respectively. Source data are provided as a Source Data ﬁle.
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In a ﬁnal step, we expressed the AP205 VLP together with
pathways for lactose, 2′-fucosyllactose and 3′-sialyllactose. We
were able to conﬁrm the addition of these sugars to the target site
on the AP205 coat protein (Fig. 3d and Supplementary Fig. 10).
Comparison of the extract ion chromatograms suggest that we
have occupancies in the range of 50%, 40%, and 5% for the
respective glycans, indicating that some improvement in pathway
efﬁciency will be necessary to achieve quantitative modiﬁcation of
highly multivalent protein assemblies with more complex glycan
structures. Native agarose gel electrophoresis conﬁrmed that
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Fig. 3 Glycosylation of megadalton protein assemblies. Glycosylation sites were introduced into surface-exposed regions of three self-assembling
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HCD–MS/MS spectra (Supplementary Fig. 10).
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particle assembly was not disrupted by these modiﬁcations
(Supplementary Fig. 10).
Together, these ﬁndings demonstrate that cytoplasmic NGT-
based glycoengineering is a powerful platform for generation of
deﬁned surface-modiﬁed proteinaceous assemblies with possible
applications as next generation anti-carbohydrate vaccines, drug-
delivery vehicles, and multifunction molecular containers.
Discussion
Chemical synthesis of glycans51 and glycoproteins52 is challen-
ging, and synthetic access to many structures requires combined
chemo-enzymatic approaches53,54. On the other hand, cells and
organisms readily produce a variety of complex carbohydrates
and glycoconjugates but often only tiny amounts are produced
and they are present as components of complex mixtures of
similar structures. A practical solution is to genetically engineer
cell lines or bacterial strains to produce desired glycoconjugates.
To access new areas of glycan and protein structural space, E. coli
expression systems have the distinct advantage that they lack
native protein glycosylation machinery, thus permitting the
design and installation of orthogonal glycosylation pathways.
In this work, we introduce a platform for glycoprotein engi-
neering in E. coli. Two features of this platform make it unique
among existing glycoengineering efforts: (i) its use of sequential
rather than en bloc glycosylation and (ii) its location in the
cytoplasm. Sequential glycosylation enables the construction of a
glycan directly on the protein substrate by successive action of
different glycosyltransferases. This provides a greatly simpliﬁed
pathway architecture compared to en bloc glycosylation, which
requires preassembly of the glycan as an LLO, enzymatic ﬂipping
of the LLO to the lumen of the periplasm, followed by transfer of
the entire oligosaccharide onto the protein.
The glycosylation pathways established in this work yield
biologically relevant glycan structures, a number of which have
important applications as research and medical reagents. 2′-
fucose and 3′-sialic acid modiﬁcations are present on glycolipids
and glycoproteins on the surface of human cells. 3′-sialyllactose is
the head group of the GM3 ganglioside and the ligand of avian
inﬂuenza virus55. The incorporation of host-derived GM3 into
the membrane of HIV-1 particles mediates infection of immune
cells via interaction with Siglec-156. Fucosylated glycans are
abundant on the lumenal surface of intestinal epithelial cells and
were recently shown to be ligands for cholera toxin57. The ﬁnding
that 2′-fucosyllactose and fucose-bearing polymers are competi-
tive inhibitors of cholera toxin binding44 suggests promising
applications for multivalent fucosylated structures produced with
this system.
Two of our prototype pathways address the biosynthesis of
capsular polysaccharides from N. meningitidis. The serogroup C
polysaccharide is the protective antigen targeted by the menin-
gococcal vaccine incorporated in the current childhood
schedule. In order to raise a long-lasting and protective
immune response against the polysaccharide, it is ﬁrst puriﬁed
from large-scale cultivation of the pathogen, then chemically
cross-linked to an immunogenic carrier protein58. Recombinant
synthesis of complete glycoconjugate vaccines would reduce the
cost of production by orders of magnitude, and promises to
increase access in developing countries where the burden of
disease is highest.
A unique feature of this platform is its location in the
bacterial cytoplasm, the most popular compartment for protein
expression in engineering and directed evolution studies. Engi-
neered proteins that are cytoplasmically produced include
catalysts for treating nerve agent intoxication59 or leukemia60, a
diversity of antibody mimetics31, and self-assembling protein
nanostructures18,23–25. Glycosylation of these proteins has the
potential to transform their application as therapeutic reagents
by, for example, reducing immunogenicity61, increasing circu-
lating half-life32, targeting the molecule to particular cells or
tissues62,63, or inducing a glycan-speciﬁc immune response64.
A caveat of this system is that the initiating enzyme, ApNGT,
requires access to the targeting N-x-S/T motif in an unfolded
state. In this study, we introduced glycosylation sites on accessible
terminal polypeptides and we have previously demonstrated
efﬁcient modiﬁcation of a ﬂexible loop inserted into a folded
domain32. We expect that glycosylation sites in structured seg-
ments of a protein domain are likely to be challenging substrates
for this cytoplasmic glycosylation platform.
A further challenge that is addressed in this work is the gen-
eration of multivalent glycoconjugates. Due to the relatively low
afﬁnities of glycan–protein interactions, biological systems typi-
cally exploit multiple simultaneous interactions to achieve func-
tionally relevant avidities41. Multivalent interactions are made
possible by the dense display of glycan epitopes, for example, the
plasma membrane of a mammalian cell is decorated with several
million glycans65, and the mucin, MUC1, can be glycosylated at
one in every four amino acids along the polypeptide chain66. This
platform provides facile access to multivalent glycan display
either along a single polypeptide chain or in a deﬁned geometric
arrangement on the surface of proteinaceous nanostructures.
For application of multivalent glyco-structures, pathway efﬁ-
ciencies will need to be improved. Although glucose and lactose
were efﬁciently installed on both mono- and multivalent sub-
strates, the assembly of larger oligosaccharides was less efﬁcient.
Bottlenecks may result from: (i) insufﬁcient nucleotide sugar
availability, (ii) unbalanced expression of glycosyltransferases,
and/or (iii) low speciﬁc activity of glycosyltransferases towards
heterologous substrates. We are currently developing high-
throughput screens as a basis for the metabolic and enzyme
engineering required to achieve quantitative glycosylation of
highly multivalent glycostructures.
In summary, the Glycoli platform advances protein gly-
coengineering on several fronts. It provides access to mammalian
and bacterial glycan structures that are not accessible to existing
en bloc glycoengineering platforms. It brings glycoprotein bio-
synthesis to the cytoplasmic compartment, thus converting the
vast majority of engineered proteins—including therapeutic
enzymes, antibody mimetics, and self-assembling proteins—into
accessible substrates. Finally, it replicates natural forms of mul-
tivalent glycan display by enabling the production of heavily
glycosylated polymers and particles.
Methods
General plasmid design and construction. Glycosyltransferases used to build-up
glycosylation pathways are listed in Supplementary Table 1. Strains and plasmids
used in this study are listed in Supplementary Table 2. Each glycosyltransferase
BioBrick (GTBb) comprised a single expression cassette including a variable pro-
moter (lacUV5, or T5), a ribosome-binding site, the relevant open-reading frame,
and a T7 terminator, all ﬂanked by the BioBrick preﬁx and sufﬁx (Supplementary
Fig. 1). Open-reading frames were codon optimized and synthesized (Genscript),
then cloned into the BioBrick expression cassette via BamHI/AvrII. Construction
of multi-brick pathways was carried out by standared restriction enzyme-based
BioBrick cloning38. All constructs were conﬁrmed by Sanger sequencing
(Microsynth).
Construction of plasmids AaLS-13-GI and AaLS-13-GIII. Plasmid pMG-AaLS-
1320 was used as the starting point for cloning glycosylation competent AaLS
constructs. Two DNA fragments, GI-temp and GIII-temp, coding for glycosylation
tags containing one and three glycosylation sites, respectively, ﬂanked by a Gly-Ser
linker and a C-terminal hexahistidine tag, were generated. GI-temp was con-
structed from the primers FW_GI_temp (5′-GGATCAGGCGCTCATGCGA
CGGCGAACGCTACCGCTCAT) and RV_GI_temp (5′-GTGATGATGGTGA
TGGTGGCTAGCATGAGCGGTAGCGTT). GIII-temp was assembled from the
primers FW_GIII_temp (5′-GGATCAGGCGCTAATGCGACGGCGAACGCTA
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CCGCTAAT) and RV_GIII_temp (5′-GTGATGATGGTGATGGTGGCTAGCA
TTAGCGGTAGCGTT). In both cases, overhanging ends were ﬁlled in by the
Klenow fragment of DNA Polymerase I. XhoI and SpeI sites were introduced using
primers FW_XhoI_GI (5′-GCAGCTCGAGGGGAGTGGATCAGGCGCTCAT
GCG) or FW_XhoI_GIII (5′-GCAGCTCGAGGGGAGTGGATCAGGCGCTAA
TGCG) for the 5′ region and RV_SpeI_G (5′-CTCCTCACTAGTTAGTGATGA
TGGTGATGGTGGCTAG) for the 3′ region. The resulting 93 bp PCR products
were digested with XhoI and SpeI to give 82 bp fragments. These fragments were
ligated with the correspondingly digested 4993 bp fragment from pMG-AaLS-13 to
obtain plasmids pMG-AaLS-13-GI and pMG-AaLS-13-GIII.
Bacterial strains and growth conditions. E. coli DH5α was used for maintenance
and propagation of plasmids. DH5α cells were cultivated at 37 °C in Luria-Bertani
(LB) medium in shaker ﬂasks or on LB plates containing 1.5% agar (w/v), sup-
plemented with appropriate antibiotics (kanamycin 50 µg mL−1, chloramphenicol
35 µg mL−1, trimethoprim 50 µg mL−1).
Expression of glycosylated substrates, both proteins and VLPs was carried out in
the E. coli K-12 derivative strain W3110 ΔnanAK ΔlacZ. Knock-out of the nanAK
prevents catabolism of sialic acid, whilst the β-galactosidase encoding gene lacZ was
knocked-out to avoid cleavage of N-Lac36. Terriﬁc Broth (TB) supplemented with
0.5M NaCl was used for protein expression. Cultures were grown at 37 °C to an
OD600 of ~0.7. Expression was induced by the addition of 1 mM IPTG, and where
necessary also 0.4% L-arabinose. Cultures were grown for a further 16–20 h at 28 °C
in the presence of inducing agents. In the case of fucosylated structures, the culture
was spiked with 2 g L−1 of L-fucose. When cultivating strains with pHT081, the
culture was spiked with 5mM Neu5Ac. Cell pellets were harvested by centrifugation,
washed once with PBS and stored at −20 °C.
Puriﬁcation of GFP constructs. The cell pellet from a 20mL expression cultures
was resuspended in 5 mL lysis buffer (60 mM Tris pH 8, 1 mM MgCl2, 150 mM
NaCl) supplemented with 20 µg mL−1 Dnase I (Roche), 1 mg mL−1 lysozyme
(Sigma), Protease Inhibitor Cocktail (Roche), and 2 mM β-mercaptoethanol
(Sigma). Cells were lysed by sonication. Samples were cleared by centrifugation at
15,000 × g, 15 min at 4 °C. The supernatant was further cleared by ﬁlter sterilization
prior to afﬁnity puriﬁcation.
The sfGFP constructs were puriﬁed via Ni-NTA beads (Macherey-Nagel).
Clariﬁed lysates were loaded onto pre-equilibrated beads, then beads were washed
with high salt and urea buffer (60 mM Tris pH 8, 1M NaCl, 2 M Urea) and
washing buffer (60 mM Tris pH 8, 150 mM NaCl, 30 mM Imidazole). Proteins
were eluted using elution buffer containing 250 mM Imidazole (60 mM Tris, 150
mM NaCl). Samples were concentrated and buffer exchanged into freezing buffer
(50 mM Tris pH 8, 50 mM NaCl, 10% glycerol, 5 mM DTT) using centrifugal ﬁlter
units with a 10 kDa cut off (Amicon, Millipore).
Protein concentrations were determined by BCA assay (Pierce). Puriﬁed (glyco)
proteins were separated by Tricine–SDS–PAGE67. Gel staining was done using
colloidal Coomassie stain68. Immunoblots were performed as follows. His tag was
detected using mouse anti-His4 antibodies (1:2500, Qiagen, Cat. no. 34670), with
goat anti-mouse IgG (1:2500, Scanta Cruz Biotechnology, sc2082). Strep-tagII was
detected directly with Streptactin–HRP (1:10000, IBA, Cat. no. 2-1502-001). N-Glc
was detected using the human serum, MS14 (1:3500)28,42, with mouse anti-human
IgG Fc (1:5000, Southern Biotech, Cat. no. 9040-05).
Puriﬁcation of polysialylated proteins. The polysialylated fraction of a GFP
sample was puriﬁed via preparative anion exchange chromatography. The eluate
from NiNTA beads was desalted and loaded onto a 2 mL Mono Q column
(5/50 GL) pre-equilibrated with buffer A (20 mM Tris pH 7.5). Proteins were
eluted in a gradient up to 100% buffer B (20 mM Tris pH 7.5, 1 M NaCl) at a ﬂow
rate of 1 mL/min with online absorbance measurement at 280 nm. Polysialylated
fractions were collected, desalted, and analyzed by SDS–PAGE and analytical anion
exchange chromatography. Polysialylated proteins were further analyzed by
immunoblot with antibodies or antisera against the relevant serogroup. To detect
proteins carrying the NmB serotype glycan, the anti-PSA IgG2a (clone name: 735),
Kappa antibody was used (1:1000, Absolute Antibody, Cat. no. Ab00240-2.0)
followed by goat anti-mouse IgG-HRP (1:2500, Santa Cruz Biotech., sc-2005). To
detect NmC capsular polysaccharide, antiserum (222301, BD) was puriﬁed using a
Protein A HP SpinTrap column (GE Healthcare). The eluent was diluted 1:1000 for
immunoblotting, then detected with goat anti-Rabbit-IgG-HRP (1:3000, BioRad,
172-1019) secondary. Uncropped images of all blots and gels are provided in the
Source Data ﬁle.
Analytical anion exchange chromatography. For characterizing chain length
heterogeneity of polysialylated GFP samples, 3 μg of protein was separated on a
ProPac SAX column (Dionex) with online ﬂuorescence detection. Proteins were
loaded on a column equilibrated with 20 mM Tris–HCl pH 7.5, then separated
with a gradient from 0 to 600 mM NaCl, over 24 min, in 20 mM Tris–HCl
at pH7.5.
Puriﬁcation of AP205 VLPs. Expression pellets were resuspended in 5 mL lysis
buffer (50 mM Tris pH 6.8, 150 mM NaCl, 1 mM MgCl2, 0.1% Triton x-100) per
gram of wet weight, then supplemented with 1 mgmL−1 lysozyme, 20 µg mL−1
Dnase I, and 0.5 mM PMSF. Lysis was allowed to proceed for 100 min at 37 °C with
shaking. Lysis was completed by sonication. Samples were cleared by centrifugation
at 25,000 × g during 30 min at 4 °C. AP205 VLPs were puriﬁed via StrepTactin
Sepharose beads (Macherey-Nagel). VLPs were bound to StrepTactin resin in batch
for 60 min at 25 °C. After washing the beads (wash buffer: 50 mM Tris pH 6.8,
150 mM NaCl, 2 mM EDTA), the VLPs were eluted using wash buffer supple-
mented with 5 mM desthiobiotin (Sigma). Protein concentration was estimated
based on absorbance at 260 and 280 nm and accounting for packaged RNA69. VLPs
were exchanged into freezing buffer (50 mM Tris pH 6.8, 150 mM NaCl, 10%
glycerol, 2 mM EDTA) using 100 kDa centrifugal ﬁlters (Amicon, Millipore), and
stored at −80 °C after freezing in liquid nitrogen.
VLPs were separated by Tricine–SDS–PAGE and native agarose electrophoresis
on 0.6% TAE agarose.
Puriﬁcation of I53-50-v4. Expression pellets were lysed as described for the
AP205 VLP (above). The I53-50-v4 particles were puriﬁed via Ni-NTA beads.
Particles were bound in batch, then transferred to a column and washed with 20
column volumes (CV) of wash buffer (50 mM Tris pH 6.8, 150 mM NaCl, 20 mM
imidazole). Protein was eluted with four CVs elution buffer (50 mM Tris pH 6.8,
150 mM NaCl, 250 mM imidazole). Samples were concentrated and buffer
exchanged into freezing buffer (50 mM Tris pH 6.8, 150 mM NaCl, 10% glycerol)
using centrifugal ultraﬁltration units (MWCO 100 kDa).
Production and puriﬁcation of AaLS-13 constructs. 14 mL PS tubes (Greiner
bio-one 191161) were ﬁlled with 5 mL LB media (LB Broth, Miller–DIFCO 244610)
containing 100 μg mL−1 ampicillin and 25 μg mL−1 chloramphenicol. Following
inoculation with a single picked colony from BL21-Gold cells transformed with
pMA933 and the different AaLS-13 plasmids, the cultures were grown at 37 °C and
230 rpm. When the OD600 reached 1.1–1.5, the cultures were induced with 2 μL 1M
IPTG (Fluorochem M02726 to a ﬁnal concentration of 0.4 mM). After culturing at
25 °C for 18 h and 230 rpm, cells were harvested by centrifugation at 5000 × g and
4 °C for 45 min. Cell pellets were stored at −20 °C until use. Each cell pellet was re-
suspended in 400 μL 50mM sodium phosphate buffer, pH 8, containing 300 mM
NaCl and 10 mM imidazole and supplemented with lysozyme (0.1 mg mL−1),
DNase I (5 μg mL−1), and RNase A (5 μg mL−1) and protease inhibitor cocktail
and incubated for 1 h at room temperature before sonication in 1.5 mL Eppendorf
tubes. Cellular debris was removed by centrifugation at 22,000 × g for 10 min at
room temperature. The lysate was loaded onto a 50 μL suspension of a Ni-NTA
sepharose resin (Qiagen) in a centrifugal column unit (Spin column 0.1 mL,
G-biosciences 786-719) and all centrifugation steps were done at 100 × g for 30 s.
After washing with 10 CVs of 50 mM phosphate, pH 8, 300 mM NaCl containing
20 and 40 mM imidazole, proteins were eluted with 50 μL 10 mM sodium phos-
phate, pH 8, containing 100 mM EDTA.
Transmission electron microscopy. Nanoparticle suspensions were adsorbed on
carbon-coated grids and stained with 2% (w/v) uranyl acetate (pH 4). Grids were
examined with an FTS Morgagni 268 electron microscope ﬁtted with a 100 kV
tungsten emitter and 1376 × 1032 pixel CCD detector.
Glycoprotein analysis by LC–MS/MS. To prepare glycosylated substrates for MS/
MS analysis, 50 µg of protein was taken and incubated for 1 h at 37 °C with 100 µL
50 mM DTT in ABC buffer (0.05 M NH4HCO3 in water, pH 8.5) to alkylate the
protein. 100 µL of 65 mM IAA in ABC buffer was added for a further hour at 37 °C.
The substrates were digested overnight at 37 °C using either 10 µL of a 1 µg µL−1
trypsin in the case of (multivalent) glycosylated proteins or LysC endopeptidase
solution for glyco-VLPs. The samples were acidiﬁed the next morning using formic
acid, prior to ZipTip (Millipore) clean-up of the samples.
Samples were analyzed on a calibrated Q ExactiveTM mass spectrometer
(Thermo Fisher Scientiﬁc) coupled to a Waters Acquity UPLC M-Class system
with a PicoviewTM nanospray source 500 model (New Objective). The tryptic
samples were dissolved in 2% acetonitrile, 0.1% formic acid, loaded onto an
Acclaim PepMap 100 trap column (75 μm× 20mm, 100 Å, 3 μm particle size) and
separated on a nanoACQUITY UPLC BEH130 C18 column (75 μm× 150mm,
130 Å, 1.7 μm particle size), at a constant ﬂow rate of 300 nL min−1, with a column
temperature of 50 °C and a linear gradient of 2−22% acetonitrile, 0.1% formic acid
in 59 min, and then 22–32% acetonitrile, 0.1% formic acid in 11 min, followed by a
sharp increase to 98% acetonitrile in 2 min and then held isocratically for another
10 min. For DDA analysis, one scan cycle comprised of a full scan MS survey
spectrum, followed by up to 12 sequential HCD scans based on the intensity. For
glycosylation proﬁling analysis, full-scan MS spectra (300–1800m/z) were acquired
in the FT-Orbitrap at a resolution of 70,000 at 400m/z, while HCD MS/MS spectra
were recorded in the FT-Orbitrap at a resolution of 35,000 at 400m/z. HCD MS/MS
spectra were performed with a target value of 1e5 by the collision energy setup at a
normalized collision energy of 22. To conﬁrm each glycopeptide structure, MS and
MS/MS spectra of the corresponding species were annotated manually.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
The authors declare that most data supporting the ﬁndings of this study are available
within the paper, Supplementary Information, and the Source Data ﬁle. The raw data
underlying peptide LC–MS/MS analysis will be made available by the corresponding
author upon request. The source data underlying Figs. 1b–f, 2a, b, and Supplementary
Figs. 4a–c, 7e, and 10a, b are provided as a Source Data ﬁle. Any other relevant data is
available from the authors upon request.
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